Stanford Pathology Breach Academia: Research trainee talk seminars designed for career development within academia and the exciting and innovative biotech industry
We invite you to a unique seminar series and networking opportunity that has been designed for you. As promised, we have been hard at work, designing a seminar series focused on your career development and the wide open and exciting space at the interface of academia and biotech. This seminar series, by invitation with RSVP requested, is designed to provide a larger view of some of the most exciting developments at the interface of science and medicine, academia and biotech, and to provide an opportunity to meet with key thought leaders. We are living through an unprecedented period of exciting change in how we do science – how we go from discovery to new diagnostics, precision health approaches, and new therapeutics, Scientific leaders of the future will be well served by understanding this ecosystem, and these are individuals you may wish to know. — Paul Mischel
Paul Mischel, MD
Professor and Vice Chair for Research, Department of Pathology
Professor, By Courtesy, Department of Neurosurgery
Institute Scholar, Sarafan ChEM-H
Stanford University
2023 Fall Seminar Series
October • November • December
Benjamin F. Cravatt, PhD
Professor and Gilula Chair of Chemical Biology, Department of Chemistry:
The Scripps Research Institute
Monday, December 11, 2032 [3-6 PM PST]
LOCATION: Li Ka Shing Center for Learning and Knowledge
LECTURE: 3-4 pm in LK101
RECEPTION: 4-6 PM, LK Herb Garden
Benjamin F. Cravatt, Ph.D., is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics (acquired by Bayer). His honors include a Wolf Prize in Chemistry, a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences.
Ben obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997. Ben is a scientific co-founder of Boundless Bio.